Jin Medical International Ltd. (ZJYL)
USD 0.8
(9.59%)
USD 0.8
(9.59%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.44 Million USD | 36.28% |
| 2022 | 3.09 Million USD | -27.3% |
| 2021 | 3.23 Million USD | 13.01% |
| 2020 | 2.79 Million USD | -40.86% |
| 2019 | 4.49 Million USD | 3.31% |
| 2018 | 4.59 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 674.64 Thousand USD | -50.41% |
| 2024 Q2 | 674.64 Thousand USD | 0.0% |
| 2023 Q4 | 1.2 Million USD | 99.6% |
| 2023 FY | - USD | 36.28% |
| 2023 Q1 | 942.96 Thousand USD | 41.7% |
| 2023 Q2 | 1.88 Million USD | 99.73% |
| 2023 Q3 | 603.62 Thousand USD | -67.95% |
| 2022 Q4 | 665.44 Thousand USD | 0.0% |
| 2022 Q3 | 665.44 Thousand USD | 14.51% |
| 2022 Q2 | 581.11 Thousand USD | -0.0% |
| 2022 Q1 | 581.11 Thousand USD | 19.86% |
| 2022 FY | - USD | -27.3% |
| 2021 Q4 | 484.84 Thousand USD | 0.0% |
| 2021 FY | - USD | 13.01% |
| 2021 Q3 | 484.84 Thousand USD | -51.72% |
| 2021 Q2 | 1 Million USD | -0.0% |
| 2021 Q1 | 1 Million USD | 49.77% |
| 2020 Q4 | 670.49 Thousand USD | 0.0% |
| 2020 FY | - USD | -40.86% |
| 2020 Q1 | 671.79 Thousand USD | -41.37% |
| 2020 Q2 | 671.79 Thousand USD | -0.0% |
| 2020 Q3 | 670.49 Thousand USD | -0.19% |
| 2019 Q1 | 1.23 Million USD | 0.0% |
| 2019 Q4 | 1.14 Million USD | 0.0% |
| 2019 Q2 | 1.23 Million USD | -0.0% |
| 2019 Q3 | 1.14 Million USD | -6.88% |
| 2019 FY | - USD | 3.31% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 107.545% |
| AngioDynamics, Inc. | -14.29 Million USD | 124.09% |
| AtriCure, Inc. | -8.1 Million USD | 142.458% |
| Avinger, Inc. | -16.34 Million USD | 121.063% |
| Azenta, Inc. | 55.15 Million USD | 93.757% |
| BioLife Solutions, Inc. | -45.23 Million USD | 107.611% |
| The Cooper Companies, Inc. | 882.8 Million USD | 99.61% |
| Daxor Corporation | 329.74 Thousand USD | -944.121% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | 126.086% |
| Femasys Inc. | -13.16 Million USD | 126.143% |
| GlucoTrack, Inc. | -7.09 Million USD | 148.553% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 63.732% |
| Hologic, Inc. | 1.29 Billion USD | 99.734% |
| ICU Medical, Inc. | 307.69 Million USD | 98.881% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 99.856% |
| KORU Medical Systems, Inc. | -9.39 Million USD | 136.628% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 92.972% |
| Innovative Eyewear, Inc. | -6.57 Million USD | 152.362% |
| Innovative Eyewear, Inc. | -6.57 Million USD | 152.362% |
| Masimo Corporation | 236.7 Million USD | 98.545% |
| Microbot Medical Inc. | -10.63 Million USD | 132.376% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 78.169% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 98.512% |
| Nephros, Inc. | -1.37 Million USD | 349.665% |
| NovoCure Limited | -175.86 Million USD | 101.958% |
| NEXGEL, Inc. | -2.73 Million USD | 226.113% |
| NEXGEL, Inc. | -2.73 Million USD | 226.113% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 103.98% |
| OraSure Technologies, Inc. | 76.15 Million USD | 95.479% |
| Pro-Dex, Inc. | 8.33 Million USD | 58.684% |
| Pulse Biosciences, Inc. | -42.36 Million USD | 108.126% |
| Predictive Oncology Inc. | -13.18 Million USD | 126.118% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | 237.06% |
| QuidelOrtho Corporation | 545.6 Million USD | 99.369% |
| Repligen Corporation | 124.29 Million USD | 97.23% |
| Sanara MedTech Inc. | -289.09 Thousand USD | 1290.91% |
| STAAR Surgical Company | 33.22 Million USD | 89.636% |
| Sharps Technology, Inc. | -8.98 Million USD | 138.338% |
| Utah Medical Products, Inc. | 24.8 Million USD | 86.12% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 98.516% |